Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

ClinicalTrials.gov ID: NCT02584933

Public ClinicalTrials.gov record NCT02584933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Study identification

NCT ID: NCT02584933
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 233 participants

Conditions and interventions

Conditions

ALK Positive Malignancies

Interventions

ceritinib Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 11, 2015 (Actual)
Primary completion: Jun 9, 2027 (Estimated)
Completion: Jun 9, 2027 (Estimated)
Last update posted: Sep 17, 2026

2015 – 2027

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Highlands Oncology Group	Fayetteville	Arkansas	72703	—
Loma Linda University	Loma Linda	California	92354	—
University of Colorado Cancer Center	Aurora	Colorado	80045	—
Maryland Oncology Hematology P A	Rockville	Maryland	20850	—
Essex Oncology of North Jersey PA	Belleville	New Jersey	07109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02584933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 17, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02584933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →